These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14567998)

  • 1. EWS/FLI function varies in different cellular backgrounds.
    Zwerner JP; Guimbellot J; May WA
    Exp Cell Res; 2003 Nov; 290(2):414-9. PubMed ID: 14567998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors.
    Zwerner JP; May WA
    Oncogene; 2001 Feb; 20(5):626-33. PubMed ID: 11313995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
    Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
    Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
    Kinsey M; Smith R; Lessnick SL
    Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
    Owen LA; Kowalewski AA; Lessnick SL
    PLoS One; 2008 Apr; 3(4):e1965. PubMed ID: 18414662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
    Prieur A; Tirode F; Cohen P; Delattre O
    Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells.
    Nozawa S; Ohno T; Banno Y; Dohjima T; Wakahara K; Fan DG; Shimizu K
    J Biol Chem; 2005 Jul; 280(30):27544-51. PubMed ID: 15919668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma.
    Wiles ET; Lui-Sargent B; Bell R; Lessnick SL
    PLoS One; 2013; 8(3):e59369. PubMed ID: 23527175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model.
    González I; Vicent S; de Alava E; Lecanda F
    J Mol Med (Berl); 2007 Sep; 85(9):1015-29. PubMed ID: 17453169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EWS/FLI1 oncogenic transcription factor deregulates GLI1.
    Zwerner JP; Joo J; Warner KL; Christensen L; Hu-Lieskovan S; Triche TJ; May WA
    Oncogene; 2008 May; 27(23):3282-91. PubMed ID: 18084326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation.
    Silvany RE; Eliazer S; Wolff NC; Ilaria RL
    Oncogene; 2000 Sep; 19(39):4523-30. PubMed ID: 11002425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma.
    Eliazer S; Spencer J; Ye D; Olson E; Ilaria RL
    Mol Cell Biol; 2003 Jan; 23(2):482-92. PubMed ID: 12509448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells.
    Thompson AD; Teitell MA; Arvand A; Denny CT
    Oncogene; 1999 Sep; 18(40):5506-13. PubMed ID: 10523827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
    Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
    PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
    Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
    Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
    Castillero-Trejo Y; Eliazer S; Xiang L; Richardson JA; Ilaria RL
    Cancer Res; 2005 Oct; 65(19):8698-705. PubMed ID: 16204038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity.
    Jaishankar S; Zhang J; Roussel MF; Baker SJ
    Oncogene; 1999 Sep; 18(40):5592-7. PubMed ID: 10523836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
    Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
    Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.